-
Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results
On February 6, 2026, Nature Communications published online a study led by Academician Xu Binghe from the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences. The single-arm Phase Ib trial evaluated the efficacy and safety of the novel oral pan-AKT inhibitor afuresertib combined with fulvestrant in previously treated patients with HR-positive/HER2-negative advanced…
-
A Decade of Pursuing Light, A Future Full of Hope: Tracing the Milestones and Defining Moments of CSCO BC
In April 2016, a pink seed took root in Beijing with the launch of preparations for the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC). Driven by vision, dedication, and perseverance, a group of Chinese physicians came together to support and empower patients with breast cancer through science, compassion, and unwavering…
-
Sino-French Breast Reconstruction Congress | Professor Hongyuan Li: Building a Bridge for Sino-French Collaboration and Advancing Breast Reconstruction Accessibility and De-escalation Strategies in Oncoplastic Surgery Through the “Chongqing Experience”
The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing, China. During the meeting, Oncology Frontier conducted an exclusive interview with Professor Hongyuan Li from the First Affiliated Hospital of Chongqing Medical University (hereafter referred to as CQMU First Hospital), one of the conference’s principal organizers.…
-
Sino-French Breast Reconstruction Congress | Professor Shengchun Liu: Pursuing Maximum Benefit with Minimal Invasiveness — Individualized Breast Reconstruction Practice and Insights for Chinese Women
The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing, China. During the meeting, Professor Shengchun Liu from the First Affiliated Hospital of Chongqing Medical University sat down with Oncology Frontier to share the “CQMU experience” accumulated over more than two decades. In the interview, Professor…
-
The World Needs Me, and I Need the World — Professor Kefeng Ding: Chinese and International Experts Discuss Key Colorectal Surgical Techniques as ICSTAC Builds New Pathways for Global Surgical Training
On April 24, 2026, the China–Spain–Canada Colorectal Surgery Clinical Practice Symposium was successfully held at the Chengdong Campus of the Second Affiliated Hospital, Zhejiang University School of Medicine. Renowned surgical experts and scholars from China, Spain, and Canada gathered to engage in in-depth academic exchanges focused on live surgical demonstrations, operative technique sharing, and presentations…
-
CURC & ARUF | Professor Linhui Wang: Addressing Complications in Retroperitoneal Surgery and Looking Ahead to the Future of Domestic Surgical Robots
At this year’s CURC & ARUF Congress, Professor Linhui Wang from the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital) served as Executive Chair of the meeting. During the Master Lecture session, he delivered a systematic analysis of the causes underlying postoperative abdominal wall bulging following retroperitoneal laparoscopic surgery. The congress also…
-
CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model
As oncology treatment paradigms continue to evolve, the multidisciplinary team (MDT) approach has become a cornerstone of modern cancer care, particularly for the management of complex malignancies. In the field of urologic oncology, MDT care integrates expertise from surgery, medical oncology, radiation oncology, imaging, pathology, and other specialties to provide individualized, full-spectrum treatment strategies that…
-
CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?
Prostate cancer is the second most commonly diagnosed malignancy and the fifth leading cause of cancer-related death among men worldwide. In recent years, with the rapid advancement of molecular biology technologies and the emergence of novel therapeutic agents, prostate cancer management has officially entered the era of precision medicine. Clinical decision-making is undergoing a profound…
Connecting Medical Expertise through Media